Boursorama interview of Alain Moussy, CEO of AB Science
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
30/09/2020 – AB Science reports its revenues for the first half of 2020
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020
08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
10/10/2019 – AB Science provides update on masitinib programs timelines
30/09/2019 – AB Science reports its revenues for the first half of 2019
19/08/2019 – AB Science announces the success of a private placement
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
05/08/2019 – AB Science provides an update on its masitinib clinical program.
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
22/07/2019 – AB Science Corporate Presentation – July 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
08/07/2019 – AB Science web conference presentation
08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
14/06/2019 – AB Science web conference presentation
12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer
10/06/2019 – AB Science is providing the upcoming news flow of the Company
10/06/2019 – AB Science is providing an updated coporate overview of the Company
05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019
04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019
04/06/2019 – AB Science web conference presentation (Part 1)
30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.